SEARCH:   Advanced

Blood, 1 July 2008, Vol. 112, No. 1, pp. 53-55. Prepublished online as a Blood First Edition Paper on April 10, 2008; DOI 10.1182/blood-2007-11-123950. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-11-123950v1 112/1/53    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jabbour, E. Articles by Cortes, J. Search for Related Content PubMed PubMed Citation Articles by Jabbour, E. Articles by Cortes, J. Related Collections Free Research Articles Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Elias Jabbour1, Hagop Kantarjian1, Dan Jones2, Megan Breeden2, Guillermo Garcia-Manero1, Susan O'Brien1, Farhad Ravandi1, Gautam Borthakur1, and Jorge Cortes1 Departments of1 Leukemia and 2 Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston Chronic myeloid leukemia (CML) with T315I mutation has been reported to have poor prognosis. We analyzed 27 patients with T315I, including 20 who developed T315I after imatinib failure (representing 11% of 186 patients with imatinib failure), and 7 of 23 who developed new mutations after second tyrosine kinase inhibitor (TKI). Median follow-up from mutation detection was 18 months. At the time of T315I detection, 10 were in chronic phase (CP), 9 in accelerated phase, and 8 in blast phase. Except for the lack of response to second TKIs (P = .002), there was no difference in patient characteristics and outcome between patients with T315I and those with other or no mutations. Patients in CP had a 2-year survival rate of 87%. Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease, with many CP patients having an indolent course. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. W. Vardiman Chronic Myelogenous Leukemia, BCR-ABL1+ Am J Clin Pathol, August 1, 2009; 132(2): 250 - 260. [Abstract] [Full Text] [PDF] W. W. Zhang, J. E. Cortes, H. Yao, L. Zhang, N. G. Reddy, E. Jabbour, H. M. Kantarjian, and D. Jones Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance J. Clin. Oncol., August 1, 2009; 27(22): 3642 - 3649. [Abstract] [Full Text] [PDF] D. Jones, S. Kamel-Reid, D. Bahler, H. Dong, K. Elenitoba-Johnson, R. Press, N. Quigley, P. Rothberg, D. Sabath, D. Viswanatha, et al. Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia: A Report of the Association for Molecular Pathology J. Mol. Diagn., January 1, 2009; 11(1): 4 - 11. [Abstract] [Full Text] [PDF] E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Blood, December 15, 2008; 112(13): 4839 - 4842. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020